TABLE 1.
FSR
|
FSR/FSRmax
|
[Ca]SR (mM)
|
||||
---|---|---|---|---|---|---|
Baseline | Nadir | Baseline | Nadir | Baseline | Nadir | |
Control | 440 ± 42 | 171 ± 28 | 0.72 ± 0.07 | 0.28 ± 0.02 | 1.04 ± 0.11 | 0.16 ± 0.02 |
WT | 364 ± 54 | 138 ± 16 | 0.66 ± 0.09 | 0.25 ± 0.01 | 0.78 ± 0.15 | 0.13 ± 0.01 |
DEL | 416 ± 20 | 162 ± 12 | 0.69 ± 0.03 | 0.27 ± 0.01 | 0.88 ± 0.07 | 0.15 ± 0.01 |
R33Q | 224 ± 28*† | 104 ± 16*† | 0.43 ± 0.05*† | 0.19 ± 0.02*† | 0.30 ± 0.08*† | 0.09 ± 0.01*† |
Global intra-SR Fluo-5N signals and estimated [Ca]SR in permeabilized myocytes infected with control adenovirus and adenoviral constructs encoding WT CASQ2, DEL, and R33Q CASQ2 mutants. FSR = F − FCAFF; FSRmax = Fmax − FCAFF; and [Ca]SR = Kd(FSR)/(FSRmax − FSR), where Kd was 400 μM (2).
Significantly different if compared with control or †if compared with WT, p < 0.05, one-way ANOVA, n of waves from 14 to 18, n of cells from 6 to 10.